Colombia Updates Diabetes Treatment Guidelines, Prioritizing Cardiovascular Health
Table of Contents
New national guidelines for type 2 diabetes treatment in Colombia, the first update in a decade, emphasize a shift towards medications proven to reduce cardiovascular risk, a leading cause of death for those with the disease.
Colombia is implementing updated national guidelines for the treatment of type 2 diabetes, marking a significant change in how doctors approach the chronic condition. The revised protocols, released this week, reflect advancements in medical knowledge and therapeutic tools over the past ten years and are designed to standardize care and improve patient outcomes. The guidelines were developed by the Colombian Association of Endocrinology, Diabetes and Metabolism, with input from over six scientific entities nationwide.
A Decade of Change Drives New Recommendations
The previous guidelines were last modified in 2016. According to a leading endocrinologist involved in the process, “there has been a very important change in the knowledge and therapeutic tools that we currently have available for the management of diabetes” in the intervening years. Historically, many diabetes medications focused solely on controlling blood sugar levels. However, these older treatments offered no protection against the development of cardiovascular disease, kidney problems, or weight gain – all significant concerns for diabetic patients.
The new recommendations prioritize SGLT2 inhibitors and GLP-1 agonists, medications demonstrably effective in mitigating these risks. GLP-1 agonists, including the widely-known Ozempic (semaglutide), have also shown promise in treating obesity.
Understanding the Science Behind the New Drugs
GLP-1 agonists have roots in research dating back to the 1970s, initially aimed at addressing type 2 diabetes – a condition characterized by the body’s inability to effectively use or produce enough insulin. These medications work by stimulating insulin secretion and reducing the production of glucagon, a hormone that raises blood glucose levels. As one expert explained, glucagon is a naturally occurring hormone within the body, not an artificial addition introduced by the drug.
The first GLP-1 agonist, Byetta, was approved for use in the United States in 2005. Subsequent research revealed its potential for weight loss, fundamentally changing the understanding of pancreatic function and glucose production.
SGLT2 inhibitors, on the other hand, target the kidneys, facilitating the elimination of excess sugar through urine. Until the 1980s, the relationship between kidney cells and glucose was poorly understood. Research in that decade identified proteins – sodium-glucose cotransporters (SGLTs) – responsible for glucose reabsorption within the kidneys. By inhibiting these proteins, SGLT2 inhibitors promote glucose excretion, improving both kidney and cardiovascular health.
Beyond Blood Sugar: A Holistic Approach to Diabetes Care
The updated guidelines represent a shift towards a more comprehensive approach to diabetes management. Doctors are now encouraged to monitor not only blood sugar levels but also other preventable risk factors, such as sedentary lifestyles and smoking.
These medications were already being prescribed in Colombia, but their formal inclusion in the national guidelines elevates their status to a first-line treatment option. As one specialist noted, “The guide seeks to establish a care path that indicates which combinations of treatments offer better results and reduce complications.”
Ongoing research is focused on developing even more effective treatments, including novel combinations of GLP-1 agonists and long-acting insulins that require less frequent administration – potentially as little as weekly injections.
Global Diabetes Prevalence and the Challenge of Underdiagnosis
Type 2 diabetes is a global health crisis, with nearly 830 million people diagnosed with the condition worldwide, according to the World Health Organization’s 2022 report. In Colombia, approximately three out of every 100 citizens live with diabetes. However, health officials are concerned about significant underdiagnosis, with an estimated 50% of cases going undetected, potentially leading to fatal consequences. Furthermore, only half of those receiving treatment are able to effectively manage their diabetes.
